# A Research Study Looking at New Protein-based Tablets in Healthy Men - Oral Formulation IV

> **NCT06642584** · PHASE1 · COMPLETED · sponsor: **Novo Nordisk A/S** · enrollment: 90 (actual)

## Conditions studied

- Healthy Volunteers Type 2 Diabetes

## Interventions

- **DRUG:** Semaglutide B
- **DRUG:** Semaglutide J
- **DRUG:** Semaglutide L
- **DRUG:** Semaglutide M
- **DRUG:** Semaglutide N

## Key facts

- **NCT ID:** NCT06642584
- **Lead sponsor:** Novo Nordisk A/S
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-10-15
- **Primary completion:** 2025-07-10
- **Final completion:** 2025-08-13
- **Target enrollment:** 90 (ACTUAL)
- **Last updated:** 2025-10-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06642584

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06642584, "A Research Study Looking at New Protein-based Tablets in Healthy Men - Oral Formulation IV". Retrieved via AI Analytics 2026-07-18 from https://api.ai-analytics.org/clinical/NCT06642584. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*